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Viral infections are one of the main human health problems in recent decades and
the cancer remains one of the most lethal diseases worldwide. The development of
new antiviral drugs for the treatment of human adenovirus (HAdV) infections continues
to be a challenging goal for medicinal chemistry. There is no specific antiviral drug
approved to treat infections caused by HAdV so far and the off-label treatments currently
available show great variability in their effectiveness. In relation to cancer, most of the
available drugs are designed to act on specific targets by altering the activity of involved
transporters and genes. Taking into account the high antiviral and antiproliferative
activity against tumor cell lines displayed by some marine natural products reported
in the literature, sixty five marine organisms were selected: 51 sponges (Porifera), 13
ascidians (Chordata), and 1 gorgonian (Cnidaria), collected from Yucatan Peninsula,
Mexico, to evaluate their antiviral activity against human adenovirus type 5 (HAdV5)
and their anticancer properties against five human tumor cell lines, namely human lung
carcinoma (A549), human skin melanoma (A2058), hepatocyte carcinoma (HepG2),
breast adenocarcinoma (MCF7), and pancreas carcinoma (MiaPaca-2). Eleven extracts
displayed anti-HAdV activity being the organic extracts of Dysidea sp., Agelas citrina,
Chondrilla sp., Spongia tubulifera, and Monanchora arbuscula the five most active ones.
On the other hand, 24 extracts showed antiproliferative activity against at least one
tumor cell line, being the extracts of the ascidian Eudistoma amanitum and the sponge
Haliclona (Rhizoniera) curacaoensis the most active ones. This work constitutes the first
wide antiviral and antiproliferative screening report of extracts from the marine sponges,
ascidians, and a gorgonian collected from the Yucatan Peninsula, Mexico.
Keywords: antiviral, antiproliferative, Yucatan Peninsula, marine organisms extracts, sponges, ascidians,
gorgonian
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INTRODUCTION
Human adenoviruses (HAdV) are non-enveloped viruses with
an icosahedral capsid containing a linear double-stranded DNA
whose size ranges from 34 to 37 kb in size (Lion, 2014).
Currently, more than 100 serotypes have been identified and
grouped into 7 HAdV species (HAdV-A to -G) in Mastadenovirus
genus (Qiu et al., 2018; HAdV Working Group, 2019). HAdV
infections are common in the human population, as indicated by
the high seroprevalence of anti-adenovirus antibodies (ranging
from 80 to 90% in sub-Saharan Africa, and from 30 to 70% in
Europe and North America), but in otherwise healthy adults,
these infections are generally mild and self-limited (Grosso
et al., 2017; Inturi et al., 2018). On the other hand, with the
advances in molecular techniques of diagnosis, HAdV have
been found to be increasingly involved in occasional cases
and outbreaks of community-acquired pneumonia (CAP) in
healthy population (Yu et al., 2015; Kajon and Ison, 2016;
Tan et al., 2016; Jonnalagadda et al., 2017; Yoon et al., 2017).
In immunocompromised patients, HAdV infections occur with
a wide clinical symptomatology including pneumonia, colitis,
hepatitis, hemorrhagic cystitis, tubule-interstitial nephritis or
encephalitis, which could result in disseminated disease with high
morbidity and mortality in this population especially in pediatric
units (Lion, 2014; Sulejmani et al., 2018).
Despite HAdV significant clinical impact, there is currently
not an approved drug to treat these infections and the off-label
antiviral drugs currently available such as ribavirin, ganciclovir
and cidofovir show high variability in their clinical efficacy
and their use is also limited by their poor bioavailability
and side effects (nephrotoxicity or bone marrow suppression).
Brincidofovir (CMX001), a lipidic conjugate of cidofovir, that
finished a phase III clinical trial in 2016 with no reported results
so far (ClinicalTrials.gov Identifier: NCT02087306) and is now
being evaluated for the treatment of serious HAdV infection or
disease (ClinicalTrials.gov Identifier: NCT02596997), represents
the only potential alternative to be used for the treatment of
HAdV infections (Toth et al., 2008; Paolino et al., 2011). Based
on this scenario, the research on additional drugs with increased
anti-HAdV efficacy is thus necessary.
On the other hand, cancer remains one of the most life-
threatening disease and an economic burden worldwide (Bray
et al., 2018). Cancer is an abnormal growth of cells and
tissues, mainly influenced by the environmental and genetic
factors of each individual. More than 277 types of cancer have
been identified and diagnosed among which prostate, breast,
lung, colon, rectum, bronchus, and urinary bladder cancers
are the predominant ones (Wogan et al., 2004; Kumar and
Adki, 2018; Khalifa et al., 2019). In 2018, approximately 18
million new cases of cancer were reported globally, resulting
in approximately 10 million deaths (Vogelstein and Kinzler,
2004; Bray et al., 2018). Currently four cancer treatments are
available, which include: surgery, radiotherapy, chemotherapy,
and immunotherapy (Topalian et al., 2012; Bray et al., 2018;
June et al., 2018). Unlike surgery and radiotherapy, which
are treatment methods mainly indicated for solid tumors,
chemotherapy is a treatment that interferes with the process of
growth and cell division in tumor cells (Ma and Wang, 2009).
Although tumor recurrence and metastasis are usual in some
cases, several drugs for cancer chemotherapy are currently in use
with a considerably high therapeutic success (Kuczynski et al.,
2013; Widmer et al., 2014).
In this regard, society has become more and more reliant upon
the availability of safe and efficacious pharmaceutical products
with fewer side effects. Considering that the marine world
provides approximately half of the total biodiversity on earth
(Aneiros and Garateix, 2004; Vo and Kim, 2010), and of course
the vast expanse of the ocean, this underwater environment
would represent an exceptional opportunity for the search of
new chemical compounds (Bhadury et al., 2006) with biological
activities for the development of new anticancer and antiviral
therapies. Today, around 29,000 new compounds have been
reported from marine species, such as sponges, ascidians, corals,
and bacteria, and they represent a huge structural diversity of
secondary metabolites with very promising candidates to be
developed as new drugs (Blunt et al., 2017; Pye et al., 2017).
Up to date, agencies such as United States Food and Drug
Administration (FDA), European Medicines Agency (EMEA),
Japanese Ministry of Health or Australia’s Therapeutic Goods
Administration have approved only 8 compounds from marine
origin as therapeutic drugs, and 22 drug candidates are in
phases I, II, or III clinical trials (Pereira, 2019). Five out of the
approved drugs are used in cancer therapies, namely Cytarabine
(ara-C), Trabectedin, Eribulin mesylate, Brentuximab vedotin,
and plitidepsin (dehydrodidemnin B), while just one is used to
treat viral infections, which is the Vidarabine (ara-A) (Jiménez,
2018). In addition, due to the current SARS-CoV-2 pandemic
situation, marine compounds have acquired special interest as
a potential source of antiviral candidates (Gentile et al., 2020;
Khan et al., 2020).
The coasts of Mexico extend along 11,122 km of maritime
littorals from the Pacific Ocean to the Caribbean Sea and the
Gulf of Mexico, where a rich marine flora and fauna can be
found (Morales et al., 2006). Even so, the underwater Mexican
ecosystems remains largely unexplored. Particularly, the Yucatan
Peninsula (YP), with 1,500 km of coastline, which includes
the Mexican States of Campeche, Yucatan and Quintana Roo
(Herrera-Silveira et al., 2004), that extends along approximately
14% of total Mexican coast and it harbors a great biological
diversity in the shore and the ocean (Bye et al., 1995). All along
the western and northern coasts of the YP, extends a region
known as the Campeche Bank (CB) with abundant coral reef
ecosystems either well offshore (>100 km, such as Alacranes reef,
Cayo Arenas, Cayo Arcas, among others) or closer to the shore
of the Yucatan state (such as Sisal, Madagascar, and Serpiente);
both have been recognized as important biodiversity hotspots
(Jordán-Dahlgren, 2002; Tunnell et al., 2007; Ortiz-Lozano et al.,
2013; Zarco-Perelló et al., 2013). Additionally, the eastern coast
of YP is part of the Mesoamerican Reef, which contains the
largest barrier reef in the Western Hemisphere, stretching nearly
700 miles from the northern tip of the YP down through the
Honduran Bay Islands (Villela et al., 2003). The potential of
Mexican marine resources along the coasts of the YP has not been
intensively investigated. Most of the few reports are limited to the
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evaluation of the biological activity of their organic extracts and
there are very few studies on the chemistry of the natural products
(Pech-Puch et al., 2020).
As far as we know, the only study of the antiviral activity in
extracts of marine organisms from the YP was the report about
the high activity of the L-carrageenan polysaccharide obtained
from the red algae Solieria filiformis (Peñuela et al., 2018). In
relation to antiproliferative activity of the marine extracts of YP,
there are only two reports corresponding to the evaluation of
30 extracts obtained exclusively from seaweeds (Moo-Puc et al.,
2009; Caamal-Fuentes et al., 2014a) which yielded, so far, four
compounds with antiproliferative activity: the diterpene dictyol
B acetate, the steroid fucosterol (Caamal-Fuentes et al., 2014b)
and the triterpenoid saponins stichloroside B2 and astichoposide
C (Graniel-Sabido et al., 2016).
In our constant search for new biological compounds, the
decision to explore the marine biodiversity of YP waters was
made. In this work, we report the most comprehensive study
undertaken to date on antiviral and antiproliferative screening
of marine invertebrate species collected along the coasts of
the YP, including a total of 65 organic extracts from sponges,
ascidians and gorgonians.
MATERIALS AND METHODS
Animal Collection and Identification
Sixty five marine organisms (51 sponges, 13 ascidians, and 1
gorgonian) were collected by snorkeling and scuba diving in two
different ecosystems in the Yucatan Peninsula, coral reef and
mangroves, during three different periods of time: September–
December 2016, January–March 2017, and September 2018. The
selected species were collected from two different regions of the
Yucatan Peninsula: Mexican Caribbean (Cozumel Island, Rio
Indio, Mahahual and Bermejo, Quintana Roo) and Campeche
Bank (Alacranes Reef and Progreso, Yucatan) in areas that were
chosen based on their rich biological diversity present in coral
reefs, islands and mangroves (Figure 1).
The samples were labeled with a code according to the
collection site, stored in plastic bags and chilled on ice during
transport to the laboratory. Voucher specimens of sponges
were deposited in the Phylum Porifera Gerardo Green National
Collection of the Institute of Marine Sciences and Limnology
(ICMyL) at the National Autonomous University of Mexico
(UNAM), Mexico City, while voucher specimens of ascidians and
gorgonian were deposited in the Marine Biology Collection at the
Autonomous University of Yucatan (UADY) in Yucatan, Mexico.
The sponges were identified at the ICMyL-UNAM (Mexico)
while the ascidians were identified at the University of Vigo
(Spain), the Autonomous University of Yucatan (Mexico) and the
University of A Coruña, Spain. Information about the taxonomic
identification of all the selected marine organisms, code numbers,
site of collection, weight of each organic extract along with the
antiviral and antiproliferative activity previously reported for
each studied species are shown in Table 1. Figures 2, 3 show
the structures of compounds with antiviral and antiproliferative
activities, respectively, previously reported from the marine
organisms present in this study.
FIGURE 1 | Sites of collection of marine organisms in the Yucatan Peninsula, Mexico.























TABLE 1 | Taxonomic information, voucher numbers, site of collection, weight of the organic extract and previously activity reported for the species studied.
Family Organism Code Site Weight (g) Antiviral activity reported Antiproliferative activity
reported
References
Clavelinidae Clavelina sp. T18-M1 Progreso, Yucatan
(Mangrove)
5.0 No No
Didemnidae Didemnum perlucidum E8-2 Rio Indio, Quintana Roo 1.8 No No
Didemnum sp. T18-M4 Progreso, Yucatan
(Mangrove)
3.5 No Pyrazin-2(1H)-ones 1–3
IC50 1.5– > 50 µg/mL
Takeara et al., 2008; Shaala
et al., 2016
Didemnum sp. E01 Bermejo, Quintana Roo 3.7
Trididemnum solidum E7-2 Rio Indio, Quintana Roo 3.4 Didemnin A-C 0.05 µg/mL
(HSV-2)
Didemnin B (4) ID50
0.002 µg/mL
Rinehart et al., 1981a,b,
1988; Crampton et al.,
1984; Sakai et al., 1995,
1996
Polysyncraton sp. EY18-8 Progreso, Yucatan 3.6 No No
Polycitoridae Eudistoma amanitum RIO18-T1 Rio Indio, Quintana Roo 3.6 No No
Eudistoma sp. TY18-2 Progreso, Yucatan 2.9 Eudistomins such 5 :
HSV-1 active
Eudistomin E (5) eudistalbin
A (6) ED50 < 5.0 ng,
3.2 mg/mL
Rinehart et al., 1987;
Adesanya et al., 1992
Polyclinidae Polyclinum sp. T18-M5 Progreso, Yucatan
(Mangrove)
1.8 No No
Ascidiidae Phallusia nigra TY18-1 Progreso, Yucatan 5.5 No No
Perophoridae Ecteinascidia sp. T18-M2 Progreso, Yucatan
(Mangrove)
9.0 Ecteinascidin 743 (7) SV40
(IC50 2 µM)
ecteinascidin 743 (7) IC50
0.16–0.68 nM
Takebayashi et al., 2001;
Dziegielewska et al., 2004
Molgulidae Molgula sp. T18-M6 Progreso, Yucatan
(Mangrove)
3.9 No No
Styelidae Polycarpa sp. E41 Alacranes Reef, Yucatan 2.4 No No
Briareidae Briareum asbestinum BA-3 Rio Indio, Quintana Roo 3.9 No Briareolate ester L (8), EC50
values of 2.4 and 9.3 µM
Gupta et al., 2011; Hall
et al., 2017
Agelasidae Agelas citrina CZE56 Cozumel, Quintana Roo 1.9 No (−)-Agelasidine C (9) IC50
10 mM
Stout et al., 2012
Agelas clathrodes E27-2 Cozumel, Quintana Roo 11.2 No No
Agelas clathrodes MA18-10 Mahahual, Quintana Roo 7.2
Agelas dilatata E25-1 Cozumel, Quintana Roo 21.3 No No
Agelas sceptrum E26-2 Cozumel, Quintana Roo 4.6 No No
Heteroxyidae Myrmekioderma
gyroderma
CZE18 Cozumel, Quintana Roo 7.5 No No
Raspailiidae Ectyoplasia ferox MA18-9 Mahahual, Quintana Roo 5.9 No No
Ectyoplasia sp. MA18-13 Mahahual, Quintana Roo 2.2 No No
Chondrillidae Chondrilla caribensis f.
hermatypica
MA18-6 Mahahual, Quintana Roo 2.1 No Thiocoraline (10) EC50
0.0095 µM
Wyche et al., 2011
Chondrilla sp. RIO18-1 Rio Indio, Quintana Roo 4.6 No No
Clathrinidae Clathrina sp. EY18-10 Progreso, Yucatan 1.4 No No











































TABLE 1 | Conitnued
Family Organism Code Site Weight (g) Antiviral activity reported Antiproliferative activity
reported
References
Clionaidae Cliona delitrix EY18-1 Progreso, Yucatan 5.2 No No
Cliona varians EY18-3 Progreso, Yucatan 1.8 No No
Dysideidae Dysidea sp. EY18-12 Progreso, Yucatan 3.3 Sesquiterpenes
hydroquinones (11–13)
from Dysidea arenaria IC50




Qiu and Wang, 2008; Wang
et al., 2020
Irciniidae Ircinia felix E9-2 Rio Indio, Quintana Roo 43.5 No Felixins F and G IC50
1.27–27.08 µM
Lai et al., 2015a,b
Ircinia felix MA18-11 Mahahual, Quintana Roo 1.7
Ircinia strobilina E24-2 Cozumel, Quintana Roo 14.1 No No
Ircinia strobilina E52 Bermejo, Quintana Roo 4.9
Spongiidae Spongia tubulifera E11-2 Rio Indio, Quintana Roo 29.8 No 3β-Hydroxyspongia-
13(16),14-dien-2-one,
spongian diterpene 17 and
ambliol C IC50
11.7–91.3 µM
Pech-Puch et al., 2019
Callyspongiidae Callyspongia longissima E28 Alacranes Reef, Yucatan 1.8 No No
Callyspongia plicifera E31 Alacranes Reef, Yucatan 1.2 No No
Callyspongia vaginalis E16 Cozumel, Quintana Roo 0.9 No No
Chalinidae Haliclona (Rhizoniera)
curacaoensis
EY18-4 Progreso, Yucatan 7.9 No No




Lhullier et al., 2019
Niphates digitalis E15 Cozumel, Quintana Roo 2.5 No No





O’Keefe et al., 1997;
Mendiola et al., 2014
Niphates erecta MA18-7 Mahahual, Quintana Roo 2.8
Niphates erecta MA18-12 Mahahual, Quintana Roo 5.5
Petrosiidae Xestospongia muta EP Alacranes Reef, Yucatan 14.1 Brominated polyacetylenic
acids IC50 6–12 µm (HIV-1)
Araguspongine C (15),
meso-araguspongine C
(16) IC50 0.43–1.02 µM
Patil et al., 1992; Dung
et al., 2019
Plakinidae Plakinastrella onkodes E3 Bermejo, Quintana Roo 4.9 No Cyclic peroxide methyl
capucinoate A (17) IC50
12 µg/mL
Horton et al., 1994;
Williams et al., 2001
Crambeidae Monanchora arbuscula E35 Alacranes Reef, Yucatan 29.8 No Polycyclic guanidine
alkaloids such as 18 GI50
1.6–>14 µM
Laville et al., 2009; Ferreira
et al., 2011
Microcionidae Clathria gomezae EY18-11 Progreso, Yucatan 1.8 No No
Clathria virgultosa E7-E34 Alacranes Reef, Yucatan 5.5 No No
Mycalidae Mycale laevis MA18-1 Mahahual, Quintana Roo 14.1 No No











































TABLE 1 | Conitnued
Family Organism Code Site Weight (g) Antiviral activity reported Antiproliferative activity
reported
References
Scopalinidae Scopalina ruetzleri DNY Rio Indio, Quintana Roo 29.8 No IC50 10.51–18.35 µg/mL Biegelmeyer et al., 2015
Scopalina ruetzleri E53 Cozumel, Quintana Roo 1.8
Scopalina ruetzleri EY18-7 Progreso, Yucatan 5.5
Halichondriidae Halichondria melanadocia E18-M1 Progreso, Yucatan
(Mangrove)
14.1 No No
Suberitidae Aaptos sp. E38 Alacranes Reef, Yucatan 4.9 4-methylaaptamine (19)
EC50 2.4 µM (HSV-1)
Aaptamine (20) IC50 (NT2)
50 µM
Souza et al., 2007;
Dyshlovoy et al., 2012
Tethyidae Tethya sp. E20 Cozumel, Quintana Roo 29.8 HSV-1, EC50 425 mg/mL,
adenovirus EC50
230 mg/mL
No Aswell et al., 1977; da Silva
et al., 2006
Geodiidae Melophlus hajdui E4 Bermejo, Quintana Roo 4.4 No No
Tetillidae Cinachyrella kuekenthali MA18-2 Mahahual, Quintana Roo 2.1 No No
Aplysinidae Aiolochroia crassa E50 Alacranes Reef, Yucatan 5.2 No No
Aiolochroia crassa MA18-4 Mahahual, Quintana Roo 8.7
Aplysina cauliformis E36 Alacranes Reef, Yucatan 6.3 No No







Aplysina fulva E42 Alacranes Reef, Yucatan 1.8 No No
Aplysina fulva EY18-5 Progreso, Yucatan 2.9
Aplysina muricyana E47 Alacranes Reef, Yucatan 4.4 No No
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FIGURE 2 | Selected structures of compounds with reported antiviral activities
displayed in Table 1. 7: ecteinascidin 743; 11: isosemnonorthoquinone; 12:
ilimaquinone; 13: smenospongine; 19: 4-methylaaptamine.
Preparation of the Organic Extracts
Sliced bodies of each species were exhaustively extracted with
the mixture of dichloromethane-methanol (1:1), three times
with 500 mL (1.5 L total volume) at 25◦C for 24 h for each
extraction. After filtration, the solvent was then removed by
rotatory evaporator at 40◦C and the crude extract stored at
−20◦C in tightly sealed glass vials.
Antiviral Assays
Viruses and Cells
Human A549 (human lung carcinoma) and 293 (human
embryonic kidney) cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, United States).
The 293β5 stable cell line overexpressing the human β5 integrin
subunit was kindly provided by Dr. Glen Nemerow (Nguyen
et al., 2010). Both cell lines were propagated in Dulbecco’s
modified Eagle medium (DMEM, Life Technologies/Thermo
Fisher) supplemented with 10% fetal bovine serum (FBS) (Omega
Scientific, Tarzana, CA, United States), 10 mM HEPES, 4 mM
L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin,
and 0.1 mM non-essential amino acids (complete DMEM).
Wild-type HAdV5 was obtained from ATCC. The HAdV5-GFP
showed in this work is a replication-defective virus with a CMV
promoter-driven enhanced green fluorescent protein (eGFP)
reporter gene cassette in place of the E1/E3 region (Nepomuceno
et al., 2007). HAdV were propagated in 293β5 cells and isolated
from the cellular lysate by cesium chloride (CsCl) density
gradient combined with ultracentrifugation. Virus concentration,
in mg/mL, was calculated with the Bio-Rad protein assay (Bio-
Rad Laboratories) and converted to virus particles/mL (vp/mL)
using 4 × 1012 vp/mg.
Plaque Assay
Natural extracts were tested using low multiplicity of infection
(MOI) (0.06 vp/cell) and at concentration of 10 µg/mL in a
plaque assay. Organic extracts that showed HAdV inhibition
greater than 70% were tested in a dose-response assay ranging
from 10 to 0.625 µg/mL in plaque assay. Briefly, 293β5 cells
were seeded in 6-well plates at a density of 4 × 105 cells per
well in duplicate for each condition. When cells reached 80–90%
confluency, they were infected with HAdV5-GFP (0.06 vp/cell)
and rocked for 2 h at 37◦C. After incubation, the inoculum
was removed and the cells were washed once with phosphate
buffered saline (PBS). The cells were then carefully overlaid with
4 mL/well of equal parts of 1.6% (water/vol) Difco Agar Noble
(Becton, Dickinson and Co., Sparks, MD, United States) and
2× EMEM (Minimum Essential Medium Eagle, BioWhittaker)
supplemented with 2× penicillin/streptomycin, 2× L-glutamine,
and 10% fetal bovine serum (FBS). The mixture also contained
the extracts in concentrations ranging from 10 to 0.625 µg/mL.
Following incubation for 7 days at 37◦C, plates were scanned
with a Typhoon 9410 imager (GE Healthcare Life Sciences) and
plaques were quantified with ImageJ (Schneider et al., 2012). This
assay was performed in duplicate.
Cytotoxicity Assay
The cytotoxicity of the extracts was analyzed by the use of
the commercial kit AlamarBlue R© (Invitrogen, Ref. DAL1025).
A549 cells at a density of 5 × 103 cells/well in 96-well plates
were seeded. Decreasing concentrations of each extract (100, 80,
60, 40, 30, 20, 10, 5, 2.5, 1.25, and 0 µg/mL) were diluted in
100 µL of Dulbecco’s Modified Eagle Medium (DMEM). Cells
were then incubated at 37◦C for 48 h following the manufacture’s
indications. The cytotoxic concentration 50 (CC50) value was
calculated using the statistical package GraphPad Prism. This
assay was performed in duplicate.
Entry Assay
The anti-HAdV activity was initially measured in an entry assay
using human A549 epithelial cells (3 × 105 cells/well in corning
black wall, clear bottom 96-well plates) infected with HAdV5-
GFP (2,000 vp/cell) in the presence of 12.5 µg/mL of each extract
and in a dose-response assay. A standard infection curve was
generated in parallel by infecting cells in the absence of extracts
using serial twofold dilutions of the virus. All reactions were done
in triplicate. Cells, viruses, and extracts were incubated for 48 h
at 37◦C and 5% CO2. Infection, measured as HAdV5-mediated
GFP expression, was analyzed using a Typhoon 9410 imager (GE
Healthcare Life Sciences) and quantified with ImageQuantTL
(GE Healthcare Life Sciences).
Statistical Analyses
Statistical analyses were performed with the GraphPad Prism
5 suite. Data are presented as the mean of duplicate/triplicate
samples ± standard deviation (SD).
Antiproliferative Assays
Colorimetric MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assays were carried out to
assess the cell viability of the samples against a panel of five
different tumor cell lines (i.e., human lung carcinoma A549
ATCC R© CCL-185TM, human skin melanoma A2058 ATCC R©
CRL-11147TM, hepatocyte carcinoma HepG2 ATCC R© HB-
8065TM, breast adenocarcinoma MCF7 ATCC R© HTB-22TM
and pancreas carcinoma MiaPaca-2 ATCC R© CRL-1420TM). All
cells were obtained from the American Type Culture Collection
(ATCC, Manassas, VA, United States). A549 cells were grown in
Ham’s F12K medium with 2 mM Glutamine, 10% FBS, 100 U/mL
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FIGURE 3 | Selected structures of compounds with reported antiproliferative activities displayed in Table 1. 1: (S)-6-(sec-butyl)-3-isopropylpyrazin-2(1H)-one; 2:
(S)-3-(sec-butyl)-6-isopropylpyrazin-2(1H)-one; 3: (S)-6-(sec-butyl)-3-isobutylpyrazin-2(1H)-one; 4: didemnin B; 5: eudistomin E; 6: eudistalbin A; 7: ecteinascidin
743; 8: briareolate ester L; 9: (−)-agelasidine C; 10: thiocoraline; 14: scalarane sesterpenoid; 15: araguspongine C; 16: meso-araguspongine C; 17: cyclic peroxide
methyl capucinoate A; 18: norbatzelladine A; 20: aaptamine; 21: 11-deoxyfistularin-3.
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penicillin and 100 µg/mL streptomycin. A2058 and HepG2 were
grown in ATCC formulated Eagle’s M essential medium (MEM)
with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate and
100 µM MEM non-essential amino acids. MCF-7 cells were
grown in the previous medium supplemented with 0.01 mg/mL
of bovine insulin. MiaPaca-2 cells were grown in DMEM with
10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin
(Audoin et al., 2013). The antiproliferative activity was assessed
after 48 h of treatment with extracts at concentrations of 30, 15,
and 7.5 µg/mL.
RESULTS AND DISCUSSION
The antiviral and antiproliferative activity of the organic extracts
from 65 marine organisms, corresponding to 51 sponges,
13 ascidians, and 1 gorgonian, collected from two different
ecosystems in the Yucatan Peninsula, coral reef and mangroves,
were evaluated. Around 17% of the extracts showed antiviral
activity against HAdV and 37% of them displayed antitumor
activity against one or more tumor cell lines.
Antiviral Screening
Marine organisms are invaluable sources of bioactive natural
products, some of them being highly significant hits for drug
development against pathogenic bacteria, viruses, and fungi
(Sagar et al., 2010). A current interest in developing antiviral
drugs has been increased since viral diseases have become major
human health problems (Sagar et al., 2010).
The results of the antiviral evaluation of marine organic
extracts are shown in Table 2. Eleven extracts displayed
significant in vitro antiviral activity against HAdV (Table 2), in
particular extracts from the ascidian Clavelina sp. and 10 sponges
which include: Agelas citrina, Myrmekioderma gyroderma,
Ectyoplasia sp., Chondrilla sp., Dysidea sp., Ircinia felix (collected
from Rio Indio, Quintana Roo), Spongia tubulifera, Monanchora
arbuscula, Aaptos sp., and Cinachyrella kuekenthali.
All the extracts were first screened in plaque assay at the
concentration of 10 µg/mL to quantify their ability to inhibit
HAdV plaque formation. The active extracts screened out
(inhibition >70%) were further evaluated to characterize their
antiviral activity (IC50) in plaque assay and their cytotoxicity
(CC50 values).
The extracts of the sponges Dysidea sp., A. citrina, Chondrilla
sp., S. tubulifera, and M. arbuscula showed the higher activity
with an inhibition > 97% at 10 µg/mL concentration and
IC50 values between 0.53 and 2.15 µg/mL in the plaque assays
(Table 2). The same sponges species showed >98% inhibition in
the entry assay at 12.5 µg/mL and IC50 values of 5.24 µg/mL
for Dysidea sp., 4.74 µg/mL for A. citrina, 3.23 µg/mL for
M. arbuscula, 2.35 µg/mL for S. tubulifera, and 1.09 µg/mL
for Chondrilla sp. The CC50 values were 19.84 µg/mL for
S. tubulifera, 19.46 µg/mL for Dysidea sp., 6.45 µg/mL for
M. arbuscula, 5.35 µg/mL for A. citrina and 2.45 µg/mL for
Chondrilla sp. The sponge S. tubulifera displayed the best
selectivity index (SI = 37.43), followed by Dysidea sp. (SI = 17.38),
A. citrina (SI = 5.05), M. arbuscula (SI = 3.00), and finally
Chondrilla sp. (SI = 1.87) (Table 2).
The ascidian Clavelina sp. displayed more than 80% inhibition
of HAdV5 infection at 10 µg/mL and an IC50 of 3.65 µg/mL in
the plaque assay. In the entry assay, it showed 39% of inhibition
at 12.5 µg/mL and in addition, it showed a CC50 value of
39.69 µg/mL and the third best selectivity index (10.87).
The sponges M. gyroderma, Ectyoplasia sp., C. kuekenthali,
Aaptos sp., and M. arbuscula showed an inhibition of HAdV5
infection ranging from 71 to 98.97% at 10 µg/mL, and IC50
values between 2.15 and 10 µg/mL. The CC50 values were
22.26 µg/mL for M. gyroderma, 39.77 µg/mL for Ectyoplasia sp.,
30.06 µg/mL for C. kuekenthali, 22.72 µg/mL for Chondrilla sp.
and 6.45 µg/mL for M. arbuscula. The selectivity index for the
five sponges showed values between 2.27 and 3.97.
For some of the organisms included in this work, the antiviral
activity of the extract had been previously described (Table 1)
as well as the activity of some of their constituent compounds
(Figure 2). That is the case of the species Trididemnum solidum,
Eudistoma sp., Amphimedon compressa, or Aaptos sp., which
extracts display significant anti-HSV or anti-SV40 activities with
IC50 ranging between 0.05 and 3.12 µg/mL (Table 1). However,
the antiviral activity showed for the former extracts did not
always correlate with their corresponding anti-HAdV activity.
Indeed, T. solidum, Eudistoma sp., and A. compressa extracts
showed very low or any anti-HAdV activity (Table 2). Moreover,
although the Thetya sp. extract displayed anti-HSV-1 activity,
its antiviral activity against HAdV was only reached at high
concentrations (Tables 1, 2).
On the contrary, the extract of the species Aaptos sp. showed
both potent anti-HSV-1 (Table 1) and significant anti-HAdV
activity (Table 2 and Figure 2). On the other hand, the anti-
HAdV activity showed by the extract from Dysidea sp. was
significantly higher than the anti-HIV activity, however, the
Niphates erecta extract was significantly more active against HIV-
1 than against HAdV (Tables 1, 2). The anti-HIV activity of both
extracts from Dysidea sp. and N. erecta was previously reported.
These data are in line with previous studies from other groups
which showed a wide variability in virus inhibition of extracts
from marine sponges and cnidarian products (Cheung et al.,
2014). Despite the fact that many authors published results of
screening of marine organisms for antiviral activity (Donia and
Hamann, 2003), there are no many screenings of marine extracts
centered on detecting anti-HAdV activity, thus these results
highlight the importance of studying further marine organisms
extracts against HAdV as sources of new antiviral drugs.
Regarding the possible mechanism of action for the extracts
from Dysidea sp. and S. tubulifera, depending on the HAdV
entry inhibition assay and cytotoxic concentrations, it may be
related to the first steps during HAdV entry into the cell host.
On the other hand, the antiviral activity of the extracts from
Clavelina sp., Aaptos sp. and Cinachyrella kuekenthali would be
associated with later steps after the entry of HAdV genomes into
the nucleus. The significant antiviral activity showed by Aaptos
sp. against both HSV-1 and HAdV suggests a potential broad-
spectrum mechanism of activity that will require further study.
The very similar IC50 values of the entry assay with those of CC50























TABLE 2 | IC50, CC50, SI, % inhibition of HAdV infection and % inhibition of HAdV entry of organic extracts of marine organisms from the Yucatan Peninsula.
Code Organism Plaque assay IC50 (µg/mL) Inhibition HAdV (%) at 10 µg/mL Entry assay IC50 (µg/mL) Inhibition HAdV (%) at 10 µg/mL CC50 SIa
T18-M1 Clavelina sp. 3.65 ± 1.56 80.95 ± 1.04 nt 38.82 ± 2.37 39.69 ± 1.30 10.87
E8-2 Didemnum perlucidum nt 22.06 ± 20.69 nt nt nt nt
T18-M4 Didemnum sp. nt 47.32 ± 1.38 nt nt nt nt
E01 Didemnum sp. nt 16.67 ± 0.00 nt nt nt nt
E7-2 Trididemnum solidum nt 0.00 ± 0.00 nt nt nt nt
EY18-8 Polysyncraton sp. nt 0.00 ± 0.00 nt nt nt nt
RIO18-T1 Eudistoma amanitum nt 0.00 ± 0.00 nt nt nt nt
TY18-2 Eudistoma sp. nt 27.47 ± 3.11 nt nt nt nt
T18-M5 Polyclinum sp. nt 38.54 ± 1.38 nt nt nt nt
TY18-1 Phallusia nigra nt 4.64 ± 10.18 nt nt nt nt
T18-M2 Ecteinascidia sp. nt 37.56 ± 4.14 nt nt nt nt
T18-M6 Molgula sp. nt 42.72 ± 17.85 nt nt nt nt
E41 Polycarpa sp. nt 23.07 ± 10.87 nt nt nt nt
BA-3 Briareum asbestinum nt 0.00 ± 0.00 nt nt nt nt
CZE56 Agelas citrina 1.06 ± 0.41 97.24 ± 0.02 4.74 ± 0.53 100.00 ± 0.00 5.35 ± 2.45 5.05
E27-2 Agelas clathrodes nt 4.92 ± 6.95 nt nt nt nt
MA18-10 Agelas clathrodes nt 6.25 ± 16.51 nt nt nt nt
E25-1 Agelas dilatata nt 0.00 ± 0.00 nt nt nt nt
E26-2 Agelas sceptrum nt 0.00 ± 0.00 nt nt nt nt
CZE18 Myrmekioderma
gyroderma
7.48 ± 1.69 71.03 ± 5.85 nt 0.00 ± 0.00 22.26 ± 2.23 2.98
MA18-9 Ectyoplasia ferox nt 35.00 ± 11.21 nt nt nt nt
MA18-13 Ectyoplasia sp. 10.00 ± 0.00 85.68 ± 7.35 nt 0.00 ± 0.00 39.77 ± 7.88 3.97
MA18-6 Chondrilla caribensis f.
hermatypica
nt 0.00 ± 0.00 nt nt nt nt
RIO18-1 Chondrilla sp. 1.31 ± 0.10 97.24 ± 3.90 1.09 ± 0.79 99.72 ± 0.29 2.45 ± 0.48 1.87
EY18-10 Clathrina sp. nt 0.00 ± 0.00 nt nt nt nt
E2-2 Leucetta floridana nt 0.00 ± 0.00 nt nt nt nt
EY18-1 Cliona delitrix nt 0.00 ± 0.00 nt nt nt nt
EY18-3 Cliona varians nt 0.00 ± 0.00 nt nt nt nt
EY18-12 Dysidea sp. 1.12 ± 0.02 98.17 ± 0.52 5.24 ± 0.50 98.24 ± 0.72 19.46 ± 0.30 17.38
E9-2 Ircinia felix 8.42 ± 0.65 80.10 ± 20.00 nt 0.00 ± 0.00 73.51 ± 33.54 8.73
MA18-11 Ircinia felix nt 51.05 ± 10.25 nt nt nt nt
E24-2 Ircinia strobilina nt 0.00 ± 0.00 nt nt nt nt
E52 Ircinia strobilina nt 0.00 ± 0.00 nt nt nt nt











































TABLE 2 | Continued
Code Organism Plaque assay IC50 (µg/mL) Inhibition HAdV (%) at 10 µg/mL Entry assay IC50 (µg/mL) Inhibition HAdV (%) at 10 µg/mL CC50 SIa
E28 Callyspongia longissima nt 0.00 ± 0.00 nt nt nt nt
E31 Callyspongia plicifera nt 54.13 ± 6.43 nt nt nt nt
E16 Callyspongia vaginalis nt 47.00 ± 5.45 nt nt nt nt
EY18-4 Haliclona (Rhizoniera)
curacaoensis
nt 51.65 ± 14.50 nt nt nt nt
E29 Amphimedon compressa nt 35.26 ± 29.17 nt nt nt nt
E15 Niphates digitalis nt 46.66 ± 9.99 nt nt nt nt
E49 Niphates erecta > 10.00 41.00 ± 8.64 nt 0.00 ± 0.00 nt nt
MA18-7 Niphates erecta nt 27.50 ± 12.68 nt nt nt nt
MA18-12 Niphates erecta nt 48.96 ± 1.47 nt nt nt nt
EP Xestospongia muta nt 18.58 ± 8.77 nt nt nt nt
E3 Plakinastrella onkodes nt 17.29 ± 0.00 nt nt nt nt
E35 Monanchora arbuscula 2.15 ± 0.37 98.97 ± 1.46 3.23 ± 1.04 100.00 ± 0.00 6.45 ± 2.41 3.00
EY18-11 Clathria gomezae nt 0.00 ± 0.00 nt nt nt nt
E7-E34 Clathria virgultosa nt 0.00 ± 0.00 nt nt nt nt
MA18-1 Mycale laevis nt 0.00 ± 0.00 nt nt nt nt
MA18-5 Mycale laevis nt 0.00 ± 0.00 nt nt nt nt
DNY Scopalina ruetzleri nt 0.00 ± 0.00 nt nt nt nt
E53 Scopalina ruetzleri nt 37.17 ± 7.51 nt nt nt nt
EY18-7 Scopalina ruetzleri nt 0.00 ± 0.00 nt nt nt nt
E18-M1 Halichondria melanadocia nt 25.86 ± 2.44 nt nt nt nt
E38 Aaptos sp. 10.00 ± 0.00 72.00 ± 10.97 nt 0.00 ± 0.00 22.72 ± 2.89 2.27
E20 Tethya sp. nt 52.89 ± 5.18 nt nt nt nt
E4 Melophlus hajdui nt 48.71 ± 2.32 nt nt nt nt
MA18-2 Cinachyrella kuekenthali 10.0 ± 0.00 73.08 ± 3.26 nt 0.00 ± 0.00 30.06 ± 9.95 3.00
E50 Aiolochroia crassa > 10.00 35.29 ± 10.70 nt 0.00 ± 0.00 nt nt
MA18-4 Aiolochroia crassa nt 0.00 ± 0.00 nt nt nt nt
E36 Aplysina cauliformis nt 0.00 ± 0.00 nt nt nt nt
E46 Aplysina fistularis nt 18.00 ± 2.82 nt nt nt nt
E42 Aplysina fulva nt 10.00 ± 3.26 nt nt nt nt
EY18-5 Aplysina fulva nt 0.00 ± 0.52 nt nt nt nt
E47 Aplysina muricyana nt 16.00 ± 12.62 nt nt nt nt
CONTROL Cidofovir nt 6.7 ± 1.6 nt nt 13.9 ± 2.7 2.07
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TABLE 3 | Antiproliferative activity in % of inhibition of organic extracts at different concentrations (in µg/mL) of marine organisms from Yucatan Peninsula.
Code Organism (µg/mL) A549a A2058b HepG2c MCF7d MiaPaca2e
30 15 7.5 30 15 7.5 30 15 7.5 30 15 7.5 30 15 7.5
T18-M1 Clavelina sp. 93 93 84 98 95 92 98 96 93 91 79 50 94 90 85
E8-2 Didemnum perlucidum 17 17 13 19 10 11 67 51 45 0 10 3 2 2 3
T18-M4 Didemnum sp. 2 9 0 4 1 3 35 8 8 4 12 7 4 4 0
E01 Didemnum sp. 2 9 3 8 0 3 8 4 2 8 11 12 8 7 3
E7-2 Trididemnum solidum 73 51 25 87 69 29 92 71 52 52 31 9 65 4 3
EY18-8 Polysyncraton sp. 15 18 9 50 23 13 80 60 53 34 23 4 8 2 3
RIO18-T1 Eudistoma amanitum 99 99 99 99 100 100 100 99 99 100 100 100 100 97 99
TY18-2 Eudistoma sp. 2 2 5 8 1 0 35 24 21 10 5 4 6 3 3
T18-M5 Polyclinum sp. 3 10 3 5 1 3 47 27 17 3 5 3 2 1 1
TY18-1 Phallusia nigra 13 10 1 2 3 4 25 7 4 8 3 1 4 0 1
T18-M2 Ecteinascidia sp. 4 4 7 5 1 3 33 9 8 2 4 7 6 4 4
T18-M6 Molgula sp. 6 11 4 16 10 1 48 29 18 1 5 3 2 0 2
E41 Polycarpa sp. 1 10 0 24 7 1 67 47 32 14 20 14 1 3 4
BA-3 Briareum asbestinum nt nt nt nt nt nt nt nt nt nt nt nt nt nt nt
CZE56 Agelas citrina 49 26 6 100 100 100 100 69 21 100 100 46 100 1 3
E27-2 Agelas clathrodes 21 17 8 20 9 6 53 26 21 0 8 3 4 2 3
MA18-10 Agelas clathrodes 8 8 1 19 1 3 29 6 6 18 5 12 4 1 2
E25-1 Agelas dilatata 22 24 16 25 18 11 63 42 39 7 2 5 6 3 4
E26-2 Agelas sceptrum 22 16 4 39 27 20 66 55 48 6 17 12 3 2 3
CZE18 Myrmekioderma gyroderma 29 12 3 74 13 1 100 100 40 73 11 1 80 0 3
MA18-9 Ectyoplasia ferox 16 18 3 6 3 4 82 1 0 4 9 3 3 6 5
MA18-13 Ectyoplasia sp. 43 20 10 37 18 5 86 47 22 41 20 5 26 4 2
MA18-6 Chondrilla caribensis f.
hermatypica
60 56 27 69 2 2 99 81 26 96 25 4 3 8 9
RIO18-1 Chondrilla sp. 1 9 1 4 2 3 24 8 1 15 9 1 3 2 3
EY18-10 Clathrina sp. 7 15 3 9 0 2 33 10 7 14 6 5 5 1 2
E2-2 Leucetta floridana 100 66 6 100 98 16 100 99 36 100 51 7 100 23 2
EY18-1 Cliona delitrix 7 13 4 16 2 2 43 23 9 13 3 7 7 8 5
EY18-3 Cliona varians 69 32 15 22 9 2 80 66 47 2 2 0 29 5 1
EY18-12 Dysidea sp. 52 12 2 64 15 1 96 65 18 86 41 4 27 3 4
E9-2 Ircinia felix 9 17 9 30 16 11 61 41 39 4 10 1 21 4 3
MA18-11 Ircinia felix 5 7 4 7 6 0 35 20 17 3 10 1 14 6 1
E24-2 Ircinia strobilina 20 22 24 39 37 38 66 47 44 10 13 3 3 1 17
E52 Ircinia strobilina 7 10 1 3 2 2 10 3 1 5 4 1 1 0 1
E11-2 Spongia tubulifera 13 12 0 35 9 0 84 55 24 31 20 1 51 16 4
E28 Callyspongia longissima 21 17 4 24 6 0 60 35 29 2 4 5 2 1 1
E31 Callyspongia plicifera 36 33 21 25 11 5 65 47 31 3 10 1 20 7 5
E16 Callyspongia vaginalis 3 8 1 6 1 2 12 5 0 14 8 9 3 2 3
EY18-4 Haliclona (Rhizoniera)
curacaoensis
100 100 99 100 100 100 100 100 100 100 100 100 100 100 100
E29 Amphimedon compressa 100 100 86 99 36 26 100 69 47 68 36 11 27 4 4
E15 Niphates digitalis 1 11 3 12 3 1 23 5 1 7 10 1 2 0 2
E49 Niphates erecta 7 12 2 13 3 1 35 15 4 24 6 12 2 0 0
MA18-7 Niphates erecta 11 15 5 9 0 2 47 26 17 31 5 4 4 0 0
MA18-12 Niphates erecta 25 16 4 51 7 1 77 49 31 2 17 5 2 4 1
EP Xestospongia muta 2 7 0 1 3 3 44 18 12 16 2 1 1 1 1
E3 Plakinastrella onkodes 100 100 84 100 98 6 100 100 90 100 56 11 100 63 3
E35 Monanchora arbuscula 67 56 48 100 100 94 99 98 93 100 99 87 100 89 90
EY18-11 Clathria gomezae 39 21 1 84 8 4 76 37 10 22 9 2 3 3 2
E7-E34 Clathria virgultosa 22 10 9 21 10 4 55 34 27 4 3 0 2 1 2
MA18-1 Mycale laevis 9 17 9 29 18 9 68 50 36 3 10 8 26 11 4
MA18-5 Mycale laevis 8 13 1 10 2 1 29 2 5 5 8 9 2 2 1
DNY Scopalina ruetzleri 66 36 21 97 34 5 94 76 46 42 1 3 4 0 2
(Continued)
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TABLE 3 | Continued
Code Organism (µg/mL) A549a A2058b HepG2c MCF7d MiaPaca2e
30 15 7.5 30 15 7.5 30 15 7.5 30 15 7.5 30 15 7.5
E53 Scopalina ruetzleri 8 11 1 9 1 2 53 26 14 5 2 5 6 2 1
EY18-7 Scopalina ruetzleri 13 24 16 31 22 13 71 51 42 3 5 2 1 3 4
E18-M1 Halichondria melanadocia 10 9 8 15 5 0 37 23 11 4 10 6 30 1 2
E38 Aaptos sp. 75 71 63 99 99 98 93 89 86 67 69 56 95 91 77
E20 Tethya sp. 81 72 58 99 91 96 90 87 83 75 72 50 97 86 8
E4 Melophlus hajdui 8 2 9 16 0 2 53 16 7 14 1 11 6 3 3
MA18-2 Cinachyrella kuekenthali 78 71 59 98 98 97 91 88 84 57 64 46 93 89 68
E50 Aiolochroia crassa 7 6 2 16 4 1 92 73 48 11 3 1 3 2 3
MA18-4 Aiolochroia crassa 11 10 4 31 13 4 95 62 36 27 6 14 2 1 1
E36 Aplysina cauliformis 20 14 3 18 11 7 52 39 28 22 7 10 3 3 4
E46 Aplysina fistularis 15 12 1 15 7 3 45 34 26 23 6 10 6 2 3
E42 Aplysina fulva 7 9 2 13 4 1 23 1 2 11 1 6 6 2 2
EY18-5 Aplysina fulva 32 24 14 23 10 4 60 46 35 1 4 3 9 1 4
E47 Aplysina muricyana 4 4 4 8 2 0 21 8 6 19 8 15 5 3 3
Reference Doxorubicin 50 µM 90 100 99 100 100
Reference MMS 4 µM 100 100 100 100 100
nt, not tested. aHuman lung carcinoma. bHuman skin melanoma. cHepatocyte carcinoma. dBreast adenocarcinoma. ePancreas carcinoma. DMSO 0% Inhibition in
all concentrations.
makes difficult to hypothesize the potential mechanism of action
for A. citrina, Chondrilla sp., and M. arbuscula extracts.
Antiproliferative Screening
The results of the antiproliferative evaluation of marine
organic extracts are shown in Table 3 as well as the
extracts (Table 1) and compounds (Figure 3) previously
described for their antiproliferative activity. Twenty-four extracts
showed growth inhibition for one or more tumor cell
lines, namely those obtained from 4 ascidians (Clavelina sp.,
T. solidum, Polysyncraton sp., and E. amanitum) and 20
sponges (A. citrina, M. gyroderma, Chondrilla caribensis f.
hermatypica, Leucetta floridana, Cliona varians, Dysidea sp.,
S. tubulifera, Haliclona (Rhizoniera) curacaoensis, A. compressa,
Plakinastrella onkodes, Monanchora arbuscula, Clathria gomezae,
Mycale laevis (collected from Mahahual, Quintana Roo),
and Scopalina ruetzleri (collected from Progreso, Yucatan
and Rio Indio, Quintana Roo), Aaptos sp., Tethya sp.,
C. kuekenthali, and Aiolochroia crassa (collected from Alacranes
Reef, Yucatan and Mahahual, Quintana Roo). Interestingly, the
extracts of two organisms, the ascidian E. amanitum and the
sponge H. (Rhizoniera) curacaoensis, displayed the most potent
antiproliferative activities with a complete growth inhibition in
all the cell lines at all concentrations tested (Table 3). No previous
studies reporting the antiproliferative activity in extracts from
these two species have been published, highlighting the value of
these two organisms as a potential source of new antiproliferative
compounds (Table 1).
The extracts of seven additional organisms, the ascidian
Clavelina sp. and the sponges P. onkodes, M. arbuscula, Aaptos
sp., Tethya sp., L. floridana, and C. kuekenthali, also showed
good activity against all the cell lines, but with variable potency
according to the concentration tested (Table 3). Nonetheless,
all of them except L. floridana, which only displays a 23%
inhibition at 15 mg/mL against the MiaPaca-2 cell line, still
meet the National Cancer Institute (NCI) guidelines to be
considered as antiproliferative, i.e., inhibition higher than 50%
at a concentration of 20 mg/mL (Hostettman, 1991; Boik, 2001).
Two extracts of the organisms, Clavelina sp. and P. onkodes,
showed more than 84% growth inhibition of the A549 cell
line at all concentrations while the six extracts displayed an
almost complete growth inhibition of the A2058 cell line at
all concentrations, except the extract of the sponge P. onkodes
that did not show any antiproliferative activity at the lowest
concentration tested. In the particular case of the cell line HepG2,
the six extracts showed more than 83% growth inhibition at all
concentrations. Regarding the MCF7 cell line, only the sponge
M. arbuscula displayed an almost complete growth inhibition at
all concentrations tested. Finally, extracts of all the organisms
except L. floridana showed antiproliferative activity according
to the NCI guidelines against the cell line MiaPaca-2. Out of
this group of seven organisms, the sponges C. kuekenthali and
L. floridana stood out as the most interesting ones due to
the lack of previous reports on the chemical composition and
antiproliferative bioactivity of their extracts. On the contrary,
previous reports on the cytotoxic properties of compounds
isolated from extracts from P. onkodes, M. arbuscula, and Aaptos
sp. make these samples less interesting for the identification of
new cytotoxic molecules, although chemical analyses should be
performed to discard the presence of other bioactive components
not previously reported in extracts of these species.
The extracts of the sponges A. citrina, M. gyroderma,
A. compressa, C. caribensis f. hermatypica, and Dysidea sp., were
active against four cell lines, being selective against some types of
cancer. The three most active extracts were those of the sponge
A. citrina that showed 100% of growth inhibition of the A2058
cell line at all concentrations tested, the HepG2 at 30 µg/mL,
the MCF7 at 30 and 15 µg/mL, and the MiaPaca-2 at 30 µg/mL,
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followed by the sponge M. gyroderma extract that showed 100%
of growth inhibition of the HepG2 at 30 and 15 µg/mL, and
more than 73% of growth inhibition against A2058, MCF7, and
MiaPaca-2 cell lines at 30 µg/mL. Finally, the extract of the
sponge A. compressa showed more than 86% of growth inhibition
of the cell line A549 at all concentrations tested, it also showed
more than 99% of growth inhibition of A2058 and HepG2 cell
lines at 30 µg/mL and more than 68% growth inhibition of
HepG2 and MCF7 cell lines at 15 µg/mL and at 30 µg/mL,
respectively. The other two sponges, C. caribensis f. hermatypica
showed more than 56% of growth inhibition of A549 (30 and
15 µg/mL), A2058 (30 µg/mL), HepG2 (30 and 15 µg/mL) and
MiaPaca-2 (30 µg/mL) and the sponge Dysidea sp. showed more
than 51% of growth inhibition against A549, A2058, HepG2,
and MCF7 cell lines to 30 µg/mL. Despite the moderate activity
found in most extracts, M. gyroderma is perhaps the most
interesting sponge of this group due to the lack of reports on its
antiproliferative activity. In the cases of A. citrina, A. compressa,
C. caribensis f. hermatypica, and Dysidea sp., once again chemical
analyses of the extracts will be necessary to asses the novelty of
their components and their potential interest for further studies.
The extracts of the rest of the organisms displayed bioactivity
to a lesser extension, hitting only a few cell lines of the panel
tested. Thus, the sponge S. ruetzleri showed more than 66%
growth inhibition of A549, A2058, and HepG2 cell lines at
30 µg/mL. On the other hand, the extract of sponge C. gomezae
showed more than 76% growth inhibition of A2058 and HepG2
cell lines at 30 µg/mL. C. gomezae seems to be the most
interesting of these two sponges due to the lack of previous
reports on cytotoxic activity of its extracts, although a preliminar
chemical investigation by LC/MS should also be performed on
the extract of S. ruetzleri before discarding the sample for further
studies. Even though Didemnum sp. had been previous shown
antiproliferative activity (Table 1) in our experience it only
showed very little activity at the highest concentration against the
HepG2 cell line, perhaps indicating that the specimens collected
by us do not contain didemnins or produce very low levels
of these potent molecules. Finally, it is worth mentioning that
more than 50% of the extracts tested showed antiproliferative
activity against the cell line HepG2, 41 extracts exhibited at least
more than 50% growth inhibition at 30 µg/mL concentration,
and the organisms, Polysyncraton sp., C. varians, S. tubulifera,
M. laevis (collected from Mahahual, Quintana Roo), S. ruetzleri
(collected from Progreso, Yucatan) and A. crassa (collected from
Alacranes Reef, Yucatan and Mahahual, Quintana Roo), only
showed activity against the cell line HepG2.
CONCLUSION
Sixty-five marine organisms, corresponding to fifty-one sponges
(Porifera), thirteen ascidians (Chordata) and one gorgonian
(Cnidaria), were collected along the coast of Yucatan Peninsula
in Mexico. They were selected on the basis of chemotaxonomical
criteria. They were extracted with organic solvents and each
extract was screened for its in vitro antiviral and antiproliferative
activity against HAdV and five tumor cell lines, respectively.
Evaluation through plaque assays showed a significant antiviral
activity for 11 extracts corresponding to 10 sponges [A. citrina,
M. gyroderma, Ectyoplasia sp., Chondrilla sp., Dysidea sp.,
M. arbuscula, Aaptos sp., C. kuekenthali, I. felix (collected from
Rio Indio, Quintana Roo), and S. tubulifera] and one ascidian
(Clavelina sp.). The extracts of the sponges Dysidea sp., A. citrina,
Chondrilla sp., S. tubulifera, and M. arbuscula showed the best
antiviral activity. The observed IC50 values of these extracts were
lower than those shown by cidofovir (IC50 = 6.7 ± 1.6 µg/mL;
CC50 = 13.9 ± 2.7), which is the drug of choice to treat
HAdV infections. However, the high cytotoxicity displayed by
A. citrina (5.35 ± 2.45 µg/mL. SI = 5.05) or Chondrilla sp.
(2.45 ± 0.48 µg/mL, SI = 1.87) generated low SI values similar
to those for cidofovir (SI = 2.07).
The high entry inhibition value registered for Dysidea sp.
and S. tubulifera suggested that the antiviral action mechanism
could be related with early steps in the HAdV replicative
cycle involving the binding, internalization by clatrin-mediated
endocytosis, endosomal escape and microtubular transport of the
viral particles to the nuclear pores of the host cell. In contrast,
the mechanism of action for the extracts from Clavelina sp.,
Aaptos sp., and C. kuekenthali would be associated with later
steps after the entry of HAdV genomes into de nucleus which
could be related with the transcription of the HAdV immediate
early gene E1A or the HAdV DNA replication process, as in the
case of cidofovir, a nucleoside analog that inhibit HAdV DNA
polymerase. A. citrina, Chondrilla sp., and M. arbuscula did not
show clear data to suggest a potential mechanism of action.
Twenty-four extracts showed antiproliferative activity that
corresponded to twenty sponges [A. citrina, M. gyroderma,
C. caribensis f. hermatypica, L. floridana, C. varians, Dysidea
sp., S. tubulifera, H. (Rhizoniera) curacaoensis, A. compressa,
P. onkodes, M. arbuscula, C. gomezae, M. laevis (collected
from Mahahual, Quintana Roo), S. ruetzleri (collected from
Progreso, Yucatan and Rio Indio, Quintana Roo), Aaptos
sp., Tethya sp., C. kuekenthali and A. crassa (collected from
Alacranes Reef, Yucatan and Mahahual, Quintana Roo) and
four ascidians (Clavelina sp., T. solidum, Polysyncraton sp.
and E. amanitum)]. Two organisms, the ascidian E. amanitum
and the sponge H. (Rhizoniera) curacaoensis, showed the best
antiproliferative activity. Additionally, more than 50% of the
extracts showed antiproliferative activity against the hepatocyte
carcinoma cell line (HepG2). According to the results reported
in this study, extracts of the tunicate E. amanitum and those
of the sponges H. (Rhizoniera) curacaoensis, C. kuekenthali,
and L. floridana proved to be the most interesting for
future studies due to their high potency against most of the
cell lines tested and the lack of previous reports on their
chemical composition.
DATA AVAILABILITY STATEMENT
The datasets presented in this article are not readily available
because the raw data supporting the conclusions of this
article will be made available by the authors upon request.
Requests to access the datasets should be directed to
JS-C, jsanchez-ibis@us.es; CJ, carlos.jimenez@udc.es; JR,
jaime.rodriguez@udc.es.
Frontiers in Marine Science | www.frontiersin.org 14 August 2020 | Volume 7 | Article 607
fmars-07-00607 August 18, 2020 Time: 17:27 # 15
Pech-Puch et al. Antiviral/Antiproliferative Activities of Marine Organisms
AUTHOR CONTRIBUTIONS
DP-P and MP-P were responsible for the recollection of
organisms and preparation of the marine extracts. JB-C and JS-C
made the antiviral assays. FR and BC did the antiproliferative
assays. PG, DP-P, HV-H, and SG-H performed taxonomic
identification. DP-P, CJ, and JR wrote the original draft. DP-
P, JR, CJ, FR, JP, and JS-C wrote, reviewed, and edited the
manuscript. All authors contributed to the article and approved
the submitted version.
FUNDING
This work was supported by Grants RTI2018-093634-B-
C22 and RTC-2016-4611-1 (AEI/FEDER, EU) from the
State Agency for Research (AEI) of Spain, both co-
funded by the FEDER Programme from the European
Union, BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme
INTERREG V A of Spain-Portugal (POCTEP). The study
was also funded by projects GRC2018/039 and Agrupación
Estratégica CICA-INIBIC ED431E 2018/03 (Consejería de
Educación, Universidad y Formación Profesional de la
Junta de Galicia) from the Xunta de Galicia (autonomous
government of the region). DP-P received a fellowship from
the program National Council of Science and Technology
(CONACYT) of Mexico and the Secretariat of Research,
Innovation and Higher Education (SIIES) of Yucatan
(Mexico). Also supported by Instituto de Salud Carlos
III, Ministerio de Economía, Industria y Competitividad,
Spanish Network for Research in Infectious Diseases
(REIPI RD16/0016/0009) – co-financed by “A way to
achieve Europe” ERDF, the Instituto de Salud Carlos III,
Proyectos de Desarrollo Tecnológico en Salud (DTS17/00130
and PI18/01191), and the Spanish Adenovirus Network
(AdenoNet, BIO2015/68990-REDT). JS-C is a researcher
belonging to the program “Nicolás Monardes” (C-0059-2018),
Servicio Andaluz de Salud, Junta de Andalucía, Spain. The
antiproliferative studies were financed with internal funds from
Fundación MEDINA.
REFERENCES
Adesanya, S. A., Chbani, M., Pais, M., and Debitus, C. (1992). Brominated
β-carbolines from the marine tunicate Eudistoma album. J. Nat. Prod. 55,
525–527. doi: 10.1021/np50082a025
Aneiros, A., and Garateix, A. (2004). Bioactive peptides from marine sources:
pharmacological properties and isolation procedures. J. Chromatogr. B
Anal. Technol. Biomed. Life Sci. 803, 41–53. doi: 10.1016/j.jchromb.2003.
11.005
Aswell, J. F., Allen, G. P., Jamieson, A. T., Campbell, D. E., and Gentry, G. A. (1977).
Antiviral activity of arabinosylthymine in herpesviral replication: mechanism
of action in vivo and in vitro. Antimicrob. Agents Chemother. 12, 243–254.
doi: 10.1128/AAC.12.2.243
Audoin, C., Bonhomme, D., Ivanisevic, J., Cruz, M., Cautain, B., Monteiro, M.,
et al. (2013). Balibalosides, an original family of glucosylated sesterterpenes
produced by the mediterranean sponge Oscarella balibaloi. Mar. Drugs 11,
1477–1489. doi: 10.3390/md11051477
Bhadury, P., Mohammad, B. T., and Wright, P. C. (2006). The current status of
natural products from marine fungi and their potential as anti-infective agents.
J. Ind. Microbiol. Biotechnol. 33, 325–337. doi: 10.1007/s10295-005-0070-3
Biegelmeyer, R., Schröder, R., Rambo, D. F., Dresch, R. R., Stout, E. P., Carraro,
J. L. F., et al. (2015). Cytotoxic effects on tumour cell lines of fatty acids from
the marine sponge Scopalina ruetzleri. J. Pharm. Pharmacol. 67, 746–753. doi:
10.1111/jphp.12366
Blunt, J. W., Copp, B. R., Keyzers, R. A., Munro, M. H. G., and Prinsep, M. R.
(2017). Marine natural products. Nat. Prod. Rep. 34, 235–294. doi: 10.1039/
c6np00124f
Boik, J. (2001). Natural Compounds in Cancer Therapy, 1st Edn, ed. S. Farnel,
(Princenton, MN: Oregon Medical Press).
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A.
(2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries freddie. CA Cancer J. Clin.
68, 394–424. doi: 10.3322/caac.21492
Bye, R., Linares, E., and Estrada, E. (1995). “Biological diversity of medicinal plants
in México,” in Phytochemistry of Medicinal Plants, eds J. T. Arnason, R. Mata,
and J. T. Romeo, (Boston, MA: Springer), 65–82. doi: 10.1007/978-1-4899-
1778-2_4
Caamal-Fuentes, E., Chale-Dzul, J., Moo-Puc, R., Freile-Pelegrin, Y., and Robledo,
D. (2014a). Bioprospecting of brown seaweed (Ochrophyta) from the Yucatan
Peninsula: cytotoxic, antiproliferative, and antiprotozoal activities. J. Appl.
Phycol. 26, 1009–1017. doi: 10.1007/s10811-013-0129-x
Caamal-Fuentes, E., Moo-Puc, R., Freile-Pelegrín, Y., and Robledo, D. (2014b).
Cytotoxic and antiproliferative constituents from Dictyota ciliolata, Padina
sanctae-crucis and Turbinaria tricostata. Pharm. Biol. 52, 1244–1248. doi: 10.
3109/13880209.2014.886273
Cheung, R. C. F., Wong, J. H., Pan, W. L., Chan, Y. S., Yin, C. M., Dan, X. L., et al.
(2014). Antifungal and antiviral products of marine organisms. Appl. Microbiol.
Biotechnol. 98, 3475–3494. doi: 10.1007/s00253-014-5575-0
Compagnone, R. S., Avila, R., Suárez, A. I., Abrams, O. V., Rangel, H. R., Arvelo,
F., et al. (1999). 11-deoxyfistularin-3, a new cytotoxic metabolite from the
caribbean sponge Aplysina fistularis insularis. J. Nat. Prod. 62, 1443–1444. doi:
10.1021/np9901938
Crampton, S. L., Adams, E. G., Kuentzel, S. L., Li, L. H., Badiner, G., and Bhuyan,
B. K. (1984). Biochemical and cellular effects of Didemnins A and B. Cancer Res.
44, 1796–1801.
da Silva, A. C., Kratz, J. M., Farias, F. M., Henriques, A. T., dos Santos, J., Leonel,
R. M., et al. (2006). In vitro antiviral activity of marine sponges collected off
Brazilian Coast. Biol. Pharm. Bull. 29, 135–140. doi: 10.1248/bpb.29.135
Donia, M., and Hamann, M. T. (2003). Marine natural products and their potential
applications as anti-infective agents. Lancet Infect. Dis. 3, 338–348. doi: 10.1016/
S1473-3099(03)00655-8
Dung, D. T., Hang, D. T. T., Yen, P. H., Quang, T. H., Nhiem, N. X., Tai, B. H.,
et al. (2019). Macrocyclic bis-quinolizidine alkaloids from Xestospongia muta.
Nat. Prod. Res. 33, 400–406. doi: 10.1080/14786419.2018.1455043
Dyshlovoy, S. A., Naeth, I., Venz, S., Preukschas, M., Sievert, H., Jacobsen, C., et al.
(2012). Proteomic profiling of germ cell cancer cells treated with aaptamine, a
marine alkaloid with antiproliferative activity. J. Proteome Res. 11, 2316–2330.
doi: 10.1021/pr300170p
Dziegielewska, B., Kowalski, D., and Beerman, T. A. (2004). SV40 DNA replication
inhibition by the monofunctional DNA alkylator Et743. Biochemistry 43,
14228–14237. doi: 10.1021/bi049407x
Ferreira, E. G., Wilke, D. V., Jimenez, P. C., de Oliveira, J. R., Pessoa, O. D. L.,
Silveira, E. R., et al. (2011). Guanidine alkaloids from Monanchora arbuscula:
chemistry and antitumor potential. Chem. Biodivers. 8, 1433–1445. doi: 10.
1002/cbdv.201000161
Gentile, D., Patamia, V., Scala, A., Sciortino, M. T., Piperno, A., and Rescifina,
A. (2020). Putative inhibitors of SARS-COV-2 main protease from a library
of marine natural products: a virtual screening and molecular modeling study.
Mar. Drugs 18, 225. doi: 10.3390/md18040225
Gopichand, Y., and Schmitz, F. J. (1979). Marine natural products: fistularin-1, -
2 and -3 from the sponge Aplysina fistularis forma fulva. Tetrahedron Lett. 20,
3921–3924. doi: 10.1016/S0040-4039(01)86465-0
Frontiers in Marine Science | www.frontiersin.org 15 August 2020 | Volume 7 | Article 607
fmars-07-00607 August 18, 2020 Time: 17:27 # 16
Pech-Puch et al. Antiviral/Antiproliferative Activities of Marine Organisms
Graniel-Sabido, M. J., Mirón-López, G., León-Deniz, L. V., Moo-Puc, R. E.,
Quintal-Novelo, C. J., Quijano, L., et al. (2016). Total NMR assignment of a new
antiproliferative triterpene oligoglycoside from the sea cucumber Astichopus
multifidus. Tetrahedron Lett. 57, 4375–4378. doi: 10.1016/j.tetlet.2016.08.051
Grosso, F., Stoilov, P., Lingwood, C., Brown, M., and Cochrane, A. (2017).
Suppression of adenovirus replication by cardiotonic steroids. J. Virol.
91:e01623-16. doi: 10.1128/jvi.01623-16
Gunasekera, S. P., and Cross, S. S. (1992). Fistularin 3 and 11-ketofistularin 3.
Feline leukemia virus active bromotyrosine metabolites from the marine sponge
Aplysina archeri. J. Nat. Prod. 55, 509–512. doi: 10.1021/np50082a020
Gupta, P., Sharma, U., Schulz, T. C., Sherrer, E. S., McLean, A. B., Robins, A. J., et al.
(2011). Bioactive diterpenoid containing a reversible “spring-loaded” (E,Z)-
dieneone Michael acceptor. Org. Lett. 13, 3920–3923. doi: 10.1021/ol201443k
HAdV Working Group (2019). HAdV Working Group. Available online at: http:
//hadvwg.gmu.edu/ (accessed June 18, 2020).
Hall, A. J., Roche, S. P., and West, L. M. (2017). Synthesis of briarane diterpenoids:
biomimetic transannular oxa-6π electrocyclization induced by a UVA/UVC
photoswitch. Org. Lett. 19, 576–579. doi: 10.1021/acs.orglett.6b03689
Herrera-Silveira, J. A., Comin, F. A., Aranda-Cirerol, N., Troccoli, L., and
Capurro, L. (2004). Coastal water quality assessment in the Yucatan Peninsula:
management implications. Ocean Coast. Manag. 47, 625–639. doi: 10.1016/j.
ocecoaman.2004.12.005
Horton, P. A., Longley, R. E., Kelly-Borges, M., McConnell, O. J., and Ballas, L. M.
(1994). New cytotoxic peroxylactones from the marine sponge, Plakinastrella
onkodes. J. Nat. Prod. 57, 1374–1381. doi: 10.1021/np50112a006
Hostettman, K. (ed.) (1991). Methods in Plant Biochemistry: Assays for Bioactivity
(Vol. 6 in Methods in Plant Biochemistry). San Diego, CA: Academic Press Ltd.
Inturi, R., Mun, K., Singethan, K., Schreiner, S., and Punga, T. (2018). Human
adenovirus infection causes cellular E3 ubiquitin ligase MKRN1 degradation
involving the viral core protein pVII. J. Virol. 92:e01154-17. doi: 10.1128/jvi.
01154-17
Jiménez, C. (2018). Marine natural products in medicinal chemistry. ACS Med.
Chem. Lett. 9, 959–961. doi: 10.1021/acsmedchemlett.8b00368
Jonnalagadda, S., Rodríguez, O., Estrella, B., Sabin, L. L., Sempértegui, F., and
Hamer, D. H. (2017). Etiology of severe pneumonia in Ecuadorian children.
PLoS One 12:e0171687. doi: 10.1371/journal.pone.0171687
Jordán-Dahlgren, E. (2002). Gorgonian distribution patterns in coral reef
environments of the Gulf of Mexico: evidence of sporadic ecological
connectivity? Coral Reefs 21, 205–215. doi: 10.1007/s00338-002-0226-9
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., and Milone, M. C.
(2018). CAR T cell immunotherapy for human cancer. Science 359, 1361–1365.
doi: 10.1126/science.aar6711
Kajon, A. E., and Ison, M. G. (2016). Severe infections with human adenovirus
7d in 2 adults in family, Illinois, USA, 2014. Emerg. Infect. Dis. 22, 730–733.
doi: 10.3201/eid2204.151403
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., et al.
(2019). Marine natural products: a source of novel anticancer drugs. Mar. Drugs
17:491. doi: 10.3390/md17090491
Khan, M. T., Ali, A., Wang, Q., Irfan, M., Khan, A., Zeb, M. T., et al. (2020).
Marine natural compounds as potents inhibitors against the main protease of
SARS-CoV-2—a molecular dynamic study. J. Biomol. Struct. Dyn. [Epub ahead
of print] doi: 10.1080/07391102.2020.1769733
Kuczynski, E. A., Sargent, D. J., Grothey, A., and Kerbel, R. S. (2013). Drug
rechallenge and treatment beyond progression-implications for drug resistance.
Nat. Rev. Clin. Oncol. 10, 571–587. doi: 10.1038/nrclinonc.2013.158
Kumar, M. S., and Adki, K. M. (2018). Marine natural products for multi-targeted
cancer treatment: a future insight. Biomed. Pharmacother. 105, 233–245. doi:
10.1016/j.biopha.2018.05.142
Lai, Y.-Y., Chen, L.-C., Wu, C.-F., Lu, M.-C., Wen, Z.-H., Wu, T.-Y., et al.
(2015a). New cytotoxic 24-homoscalarane sesterterpenoids from the sponge
Ircinia felix. Int. J. Mol. Sci. 16, 21950–21958. doi: 10.3390/ijms16092
1950
Lai, Y.-Y., Lu, M.-C., Wang, L.-H., Chen, J.-J., Fang, L.-S., Wu, Y.-C., et al. (2015b).
New scalarane sesterterpenoids from the formosan sponge Ircinia felix. Mar.
Drugs 13, 4296–4309. doi: 10.3390/md13074296
Laville, R., Thomas, O. P., Berrué, F., Marquez, D., Vacelet, J., and Amade, P. (2009).
Bioactive guanidine alkaloids from two caribbean marine sponges. J. Nat. Prod.
72, 1589–1594. doi: 10.1021/np900244g
Lhullier, C., Moritz, M. I. G., Tabalipa, E. O., Sardá, F. N., Schneider, N. F. Z.,
Moraes, M. H., et al. (2019). Biological activities of marine invertebrates extracts
from the northeast brazilian coast. Brazilian J. Biol. 80, 393–404. doi: 10.1590/
1519-6984.213678
Lion, T. (2014). Adenovirus infections in immunocompetent and
immunocompromised patients. Clin. Microbiol. Rev. 27, 441–462.
doi: 10.1128/CMR.00116-13
Ma, X., and Wang, Z. (2009). Anticancer drug discovery in the future: an
evolutionary perspective. Drug Discov. Today 14, 1136–1142. doi: 10.1016/j.
drudis.2009.09.006
Mendiola, J., Regalado, E. L., Díaz-García, A., Thomas, O. P., Fernández-Calienes,
A., Rodríguez, H., et al. (2014). In vitro antiplasmodial activity, cytotoxicity and
chemical profiles of sponge species of Cuban coasts. Nat. Prod. Res. 28, 312–317.
doi: 10.1080/14786419.2013.861835
Moo-Puc, R., Robledo, D., and Freile-Pelegrín, Y. (2009). Actividad citotóxica y
antiproliferativa in vitro de macroalgas marinas de Yucatán, México. Ciencias
Mar. 35, 345–358. doi: 10.7773/cm.v35i4.1617
Morales, J. L., Cantillo-Ciau, Z. O., Sánchez-Molina, I., and Mena-Rejón, G. J.
(2006). Screening of antibacterial and antifungal activities of six marine
macroalgae from coasts of Yucatán Peninsula. Pharm. Biol. 44, 632–635. doi:
10.1080/13880200600897569
Nepomuceno, R. R., Pache, L., and Nemerow, G. R. (2007). Enhancement of gene
transfer to human myeloid cells by adenovirus-fiber complexes. Mol. Ther. 15,
571–578. doi: 10.1038/sj.mt.6300048
Nguyen, E. K., Nemerow, G. R., and Smith, J. G. (2010). Direct evidence
from single-cell analysis that human-defensins block adenovirus uncoating to
neutralize infection. J. Virol. 84, 4041–4049. doi: 10.1128/jvi.02471-09
O’Keefe, B. R., Beutler, J. A., Cardellina, J. H., Gulakowski, R. J., Krepps, B. L.,
Mcmahon, J. B., et al. (1997). Isolation and characterization of niphatevirin,
a human-immunodeficiency-virus-inhibitory glycoprotein from the marine
sponge Niphates Erecta. Eur. J. Biochem. 245, 47–53. doi: 10.1111/j.1432-1033.
1997.t01-1-00047.x
Ortiz-Lozano, L., Pérez-España, H., Granados-Barba, A., González-Gándara, C.,
Gutiérrez-Velázquez, A., and Martos, J. (2013). The reef corridor of the
Southwest Gulf of Mexico: challenges for its management and conservation.
Ocean Coast. Manag. 86, 22–32. doi: 10.1016/j.ocecoaman.2013.10.006
Paolino, K., Sande, J., Perez, E., Loechelt, B., Jantausch, B., Painter, W., et al. (2011).
Eradication of disseminated adenovirus infection in a pediatric hematopoietic
stem cell transplantation recipient using the novel antiviral agent CMX001.
J. Clin. Virol. 50, 167–170. doi: 10.1016/j.jcv.2010.10.016
Patil, A. D., Kokke, W. C., Cochran, S., Francis, T. A., Tomszek, T., and
Westley, J. W. (1992). Brominated polyacetylenic acids from the marine sponge
Xestospongia muta: inhibitors of HIV protease. J. Nat. Prod. 55, 1170–1177.
doi: 10.1021/np50087a002
Pech-Puch, D., Pérez-Povedano, M., Lenis-Rojas, O. A., Rodríguez, J., and Jiménez,
C. (2020). Marine natural products from the Yucatan peninsula. Mar. Drugs 18,
59. doi: 10.3390/md18010059
Pech-Puch, D., Rodríguez, J., Cautain, B., Sandoval-Castro, C. A., and Jiménez,
C. (2019). Cytotoxic furanoditerpenes from the Sponge Spongia tubulifera
collected in the Mexican Caribbean. Mar. Drugs 17, 416. doi: 10.3390/
md17070416
Peñuela, A., Robledo, D., Bourgougnon, N., Bedoux, G., Hernández-Núñez, E.,
and Freile-Pelegrín, Y. (2018). Environmentally friendly valorization of Solieria
filiformis (Gigartinales, Rhodophyta) from IMTA using a biorefinery concept.
Mar. Drugs 16:487. doi: 10.3390/md16120487
Pereira, F. (2019). Have marine natural product drug discovery efforts been
productive and how can we improve their efficiency? Expert Opin. Drug Discov.
14, 717–722. doi: 10.1080/17460441.2019.1604675
Pye, C. R., Bertin, M. J., Lokey, R. S., Gerwick, W. H., and Linington, R. G.
(2017). Retrospective analysis of natural products provides insights for future
discovery trends. Proc. Natl. Acad. Sci. U.S.A. 114, 5601–5606. doi: 10.1073/
pnas.1614680114
Qiu, F. Z., Shen, X. X., Zhao, M. C., Zhao, L., Duan, S. X., Chen, C., et al. (2018).
A triplex quantitative real-time PCR assay for differential detection of human
adenovirus serotypes 2, 3 and 7. Virol. J. 15, 81. doi: 10.1186/s12985-018-0983-x
Qiu, Y., and Wang, X. (2008). A new sesquiterpenoid hydroquinone from the
marine sponge Dysidea arenaria. Molecules 13, 1275–1281. doi: 10.3390/
molecules13061275
Frontiers in Marine Science | www.frontiersin.org 16 August 2020 | Volume 7 | Article 607
fmars-07-00607 August 18, 2020 Time: 17:27 # 17
Pech-Puch et al. Antiviral/Antiproliferative Activities of Marine Organisms
Rinehart, K. L., Gloer, J. B., Cook, J. C., Mizsak, S. A., and Scahill, T. A.
(1981a). Structures of the didemnins, antiviral and cytotoxic depsipeptides
from a Caribbean Tunicate. J. Am. Chem. Soc. 103, 1857–1859. doi: 10.1021/
ja00397a055
Rinehart, K. L., Gloer, J. B., Hughes, R. G., Renis, H. E., Patrick McGovren,
J., Swynenberg, E. B., et al. (1981b). Didemnins: antiviral and antitumor
depsipeptides from a Caribbean tunicate. Science 212, 933–935. doi: 10.1126/
science.7233187
Rinehart, K. L., Kishore, V., Bible, K. C., Sakai, R., Sullins, D. W., and Li,
K. I. M. (1988). Didemnins and tunichlorin: novel natural products from the
marine tunicate Trididemnum solidum. J. Nat. Prod. 51, 1–21. doi: 10.1021/
np50055a001
Rinehart, K. L., Kobayashi, J., Harbour, G. C., Gilmore, J., Mascal, M., Holt,
T. G., et al. (1987). Eudistomins A-q, β-carbolines from the antiviral Caribbean
Tunicate Eudistoma olivaceum. J. Am. Chem. Soc. 109, 3378–3387. doi: 10.1021/
ja00245a031
Sagar, S., Kaur, M., and Minneman, K. P. (2010). Antiviral lead compounds from
marine sponges. Mar. Drugs 8, 2619–2638. doi: 10.3390/md8102619
Sakai, R., Rinehart, K. L., Kishore, V., Kundu, B., Faircloth, G., Gloer, J. B., et al.
(1996). Structure-activity relationships of the didemnins. J. Med. Chem. 39,
2819–2834. doi: 10.1021/jm960048g
Sakai, R., Stroh, J. G., Sullins, D. W., and Rinehart, K. L. (1995). Seven new
didemnins from the marine Tunicate Trididemnum solidum. J. Am. Chem. Soc.
117, 3734–3748. doi: 10.1021/ja00118a010
Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012). NIH Image to ImageJ:
25 years of image analysis. Nat. Methods 9, 671–675. doi: 10.1038/nmeth.2089
Shaala, L., Youssef, D., Badr, J., and Harakeh, S. (2016). Bioactive
2(1H)-pyrazinones and diketopiperazine alkaloids from a tunicate-
derived actinomycete Streptomyces sp. Molecules 21:1116. doi: 10.3390/
molecules21091116
Souza, T. M. L., Abrantes, J. L., Epifanio, R. D. A., Fontes, C. F. L., and Frugulhetti,
I. C. P. P. (2007). The alkaloid 4-methylaaptamine isolated from the sponge
Aaptos aaptos impairs Herpes simplex virus type 1 penetration and immediate-
early protein synthesis. Planta Med. 73, 200–205. doi: 10.1055/s-2007-96
7109
Stout, E. P., Yu, L. C., and Molinski, T. F. (2012). Antifungal diterpene alkaloids
from the caribbean sponge Agelas citrina: unified configurational assignments
of Agelasidines and Agelasines. Eur. J. Org. Chem. 2012, 5131–5135. doi: 10.
1002/ejoc.201200572
Sulejmani, N., Nagai, S., Safwan, M., Rizzari, M. D., Raoufi, M., Abouljoud,
M. S., et al. (2018). Brincidofovir as salvage therapy for adenovirus disease in
intestinal transplant recipients. Pharmacother. J. Hum. Pharmacol. Drug Ther.
38, 470–475. doi: 10.1002/phar.2094
Takeara, R., Jimenez, P. C., Wilke, D. V., Odorico de Moraes, M., Pessoa,
C., Peporine Lopes, N., et al. (2008). Antileukemic effects of Didemnum
psammatodes (Tunicata: Ascidiacea) constituents. Comp. Biochem. Physiol. Part
A Mol. Integr. Physiol. 151, 363–369. doi: 10.1016/J.CBPA.2007.02.011
Takebayashi, Y., Pourquier, P., Zimonjic, D. B., Nakayama, K., Emmert, S., Ueda,
T., et al. (2001). Correction: antiproliferative activity of ecteinascidin 743 is
dependent upon transcription-coupled nucleotide-excision repair. Nat. Med.
7:1255. doi: 10.1038/nm1101-1255c
Tan, D., Zhu, H., Fu, Y., Tong, F., Yao, D., Walline, J., et al. (2016).
Severe community-acquired pneumonia caused by human adenovirus in
immunocompetent adults: a multicenter case series. PLoS One 11:e0151199.
doi: 10.1371/journal.pone.0151199
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C.,
McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of
anti–PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454. doi: 10.1056/
NEJMoa1200690
Toth, K., Spencer, J. F., Dhar, D., Sagartz, J. E., Buller, R. M. L., Painter, G. R., et al.
(2008). Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced
mortality in a permissive, immunosuppressed animal model. Proc. Natl. Acad.
Sci. U.S.A. 105, 7293–7297. doi: 10.1073/pnas.0800200105
Tunnell, J. W., Chávez, E. A., Withers, K., and Earle, S. (eds) (2007). Coral Reefs of
the Southern Gulf of Mexico. Texas, TX: Texas A&M University Press.
Villela, P. C., Sale, P., Gold-Bouchot, G., and Kjerfve, B. (2003). Mesoamerican
Barrier Reef Systems Project: Manual of Method for the MBRS Synoptic
Monitoring Program. Selected Methods for Monitoring Physical and Biological
Parameters for Use in the Mesoamerican Region. Belize: Mesoamerican Barrier
Reef Systems Project (MBRS).
Vo, T.-S., and Kim, S.-K. (2010). Potential Anti-HIV agents from marine resources:
an overview. Mar. Drugs 8, 2871–2892. doi: 10.3390/md8122871
Vogelstein, B., and Kinzler, K. W. (2004). Cancer genes and the pathways they
control. Nat. Med. 10, 789–799. doi: 10.1038/nm1087
Wang, Q., Sun, Y., Yang, L., Luo, X., de Voogd, N. J., Tang, X., et al.
(2020). Bishomoscalarane sesterterpenoids from the sponge Dysidea granulosa
collected in the South China Sea. J. Nat. Prod. 83, 516–523. doi: 10.1021/acs.
jnatprod.9b01202
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., et al. (2014).
Review of therapeutic drug monitoring of anticancer drugs part two - targeted
therapies. Eur. J. Cancer 50, 2020–2036. doi: 10.1016/j.ejca.2014.04.015
Williams, D. E., Allen, T. M., Van Soest, R., Behrisch, H. W., and Andersen,
R. J. (2001). Glánvillic acids A and B and methyl capucinoate A, new
metabolites isolated from the Caribbean sponges Plakortis halichondrioides and
Plakinastrella onkodes. J. Nat. Prod. 64, 281–285. doi: 10.1021/np000417i
Wogan, G. N., Hecht, S. S., Felton, J. S., Conney, A. H., and Loeb, L. A. (2004).
Environmental and chemical carcinogenesis. Semin. Cancer Biol. 14, 473–486.
doi: 10.1016/j.semcancer.2004.06.010
Wyche, T. P., Hou, Y., Braun, D., Cohen, H. C., Xiong, M. P., and Bugni, T. S.
(2011). First natural analogs of the cytotoxic thiodepsipeptide thiocoraline a
from a marine Verrucosispora sp. J. Org. Chem. 76, 6542–6547. doi: 10.1021/
jo200661n
Yoon, B. W., Song, Y. G., and Lee, S. H. (2017). Severe community-acquired
adenovirus pneumonia treated with oral ribavirin: a case report. BMC Res. Notes
10:1–4. doi: 10.1186/s13104-016-2370-2
Yu, H. X., Zhao, M. M., Pu, Z. H., Wang, Y. Q., and Liu, Y. (2015). Clinical
data analysis of 19 cases of community-acquired adenovirus pneumonia in
immunocompetent adults. Int. J. Clin. Exp. Med. 8, 19051–19057.
Zarco-Perelló, S., Mascaró, M., Garza-Pérez, R., Simoes, N., Mascaró, M., Garza-
Pérez, R., et al. (2013). Topography and coral community of the Sisal Reefs,
Campeche Bank, Yucatán, México. Hidrobiológica 23, 28–41.
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Pech-Puch, Berastegui-Cabrera, Pérez-Povedano, Villegas-
Hernández, Guillén-Hernández, Cautain, Reyes, Pachón, Gómez, Rodríguez,
Jiménez and Sánchez-Céspedes. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Marine Science | www.frontiersin.org 17 August 2020 | Volume 7 | Article 607
